Page 67 - Read Online

Jiang et al. Hepatoma Res 2019;5:5 I http://dx.doi.org/10.20517/2394-5079.2018.97 Page 11 of 11

toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008;105:3933-8.
13. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
transactivation domain. Science 1996;274:948-53.
14. Pazgier M, Liu M, Zou G, Yuan W, Li C, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and
MDMX. Proc Natl Acad Sci USA 2009;106:4665-70.
15. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53
peptide. J Am Chem Soc 2007;129:2456-7.
16. Madden MM, Vera CIR, Song W, Lin Q. Facile synthesis of stapled, structurally reinforced peptide helices via a photoinduced
intramolecular 1, 3-dipolar cycloaddition reaction. Chem Commun 2009:5588-90.
17. Boal AK, Guryanov I, Moretto A, Crisma M, Lanni EL, et al. Facile and e-selective intramolecular ring-closing metathesis reactions
in 310-helical peptides: a 3D structural study. J Am Chem Soc 2007;129:6986-7.
18. Schievano E, Bisello A, Chorev M, Bisol A, Mammi S, et al. Aib-rich peptides containing lactam-bridged side chains as models of the
310-helix. J Am Chem Soc 2001;123:2743-51.
19. Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, et al. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell
2006;24:199-210.
20. Zhang F, Sadovski O, Xin SJ, Woolley GA. Stabilization of folded peptide and protein structures via distance matching with a long,
rigid cross-linker. J Am Chem Soc 2007;129:14154-5.
21. Ousaka N, Inai Y, Kuroda R. Chain-terminus triggered chiral memory in an optically inactive 310-helical peptide. J Am Chem Soc
2008;130:12266-7.
22. Cantel S, Le Chevalier Isaad A, Scrima M, Levy JJ, DiMarchi RD, et al. Synthesis and conformational analysis of a cyclic peptide
obtained via i to i+ 4 intramolecular side-chain to side-chain azide-alkyne 1, 3-dipolar cycloaddition. J Org Chem 2008;73:5663-74.
23. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, et al. Integrative analysis of complex cancer genomics and clinical profiles using
the cBioPortal. Sci Signal 2013;6:pl1.
24. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. The cBio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
25. He W, Mazzuca P, Yuan W, Varney K, Bugatti A, et al. Identification of amino acid residues critical for the B cell growth-promoting
activity of HIV-1 matrix protein p17 variants. Biochim Biophys Acta Gen Subj 2019;1863:13-24.
26. He W, Yan J, Sui F, Wang S, Su X, et al. Turning a luffa protein into a self-assembled biodegradable nanoplatform for multitargeted
cancer therapy. ACS Nano 2018;12:11664-77.
27. Dolcetti R, Giagulli C, He W, Selleri M, Caccuri F, et al. Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proc
Natl Acad Sci U S A 2015;112:14331-6.
28. Liu M, Li C, Pazgier M, Li C, Mao Y, et al. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of
malignant neoplasms. Proc Natl Acad Sci USA 2010;107:14321-6.
29. Yan J, He W, Yan S, Niu F, Liu T, et al. Self-assembled peptide-lanthanide nanoclusters for safe tumor therapy: overcoming and
utilizing biological barriers to peptide drug delivery. ACS Nano 2018;12:2017-26.
30. Niu F, Yan J, Ma B, Li S, Shao Y, et al. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating
peptide for acute myeloid leukemia therapy. Biomaterials 2018;167:132-42.
31. Yu M, Yan J, He W, Li C, Ma PX, et al. Synthetic θ-defensin antibacterial peptide as a highly efficient nonviral vector for redox-
responsive miRNA delivery. Adv Biosys 2017;1:1700001.
32. Bu B, Tong X, Li D, Hu Y, He W, et al. N-terminal acetylation preserves α-synuclein from oligomerization by blocking intermolecular
hydrogen bonds. ACS Chem Neurosci 2017;8:2145-51.
33. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6.
34. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and
inhibits p53-mediated transactivation. cell 1992;69:1237-45.
35. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
36. Linares LK, Hengstermann A, Ciechanover A, Müller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and
degradation of p53. Proc Natl Acad Sci USA 2003;100:12009-14.
37. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
38. Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov
2014;13:217-36.
39. Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, et al. Clinical overview of MDM2/X-targeted therapies. Front Oncol 2016;6:7.
40. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel
approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49:223-41.
41. Tan BX, Liew HP, Chua JS, Ghadessy FJ, Tan YS, et al. Anatomy of Mdm2 and Mdm4 in evolution. J Mol Cell Biol 2017;9:3-15.
42. Zhan C, Lu W. Peptide activators of the p53 tumor suppressor. Curr Pharm Des 2011;17:603-9.
43. Liu M, Pazgier M, Li C, Yuan W, Li C, et al. A left-handed solution to peptide inhibition of the p53-MDM2 interaction. Angew Chem
Int Ed Engl 2010;49:3649-52.